Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient
Código 300630 (Harmonized System 2012 by 6 digits)
Exchange by Territory
#permalink to sectionInternational Sales
#permalink to sectionNorway: US$122k, Main commercial destination (2024)
In 2024, the countries with the most international purchases from Mexico were Norway (US$122k), Panama (US$94.4k), Peru (US$2.19k), and Ireland (US$299).
International Purchases
#permalink to sectionGermany: US$20.5M, Main Commercial Origin (2024)
The countries with the most international sales to Mexico in 2024 were Germany (US$20.5M), United States (US$11.9M), Italy (US$8.5M), France (US$3.99M), and Ireland (US$3.87M).
Specialization
#permalink to sectionSpecialization by State
#permalink to sectionThe RCA-Complexity diagram compares the Revelead Comparative Advantages of states in Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient and the Economic Complexity Index of each state.
RCA values greater than 1 indicate that the state has comparative advantages in Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient. On the other hand, high levels of complexity (ECI) are associated with higher levels of income, potential for economic growth, lower income inequality and lower emissions.
Global Market
#permalink to sectionOrigins and Trade Destinations
#permalink to section- 0.0022%, Mexican share in global exports - 2022
- 0.5%, Mexican share in global imports - 2022
The visualizations show the global market for Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient. In both charts, Mexico stands out in order to identify its participation in the export and import market.
In 2022, the main exporting countries of Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were Germany (US$952M), Ireland (US$542M), and China (US$515M). In the same year, the main importing countries for Preparations Opacifiers for Radiologic Examinations; Diagnostic Reagents Designed to be Patient were N/A.